Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2017 Jan 26;9(1):e999.
doi: 10.7759/cureus.999.

Malignant Proliferating Trichilemmal Tumor Treated with Radical Radiotherapy: A Case Report and Literature Review

Duncan Sutherland  1 , Kathryn Roth  2 , Edward Yu  3
Affiliations
Case Reports

Malignant Proliferating Trichilemmal Tumor Treated with Radical Radiotherapy: A Case Report and Literature Review

Duncan Sutherland et al. Cureus. .

Abstract

Reported here is the first case of a malignant proliferating trichilemmal tumor treated with radical radiotherapy. Complete clinical response was achieved, and this obviated the need for aggressive surgery. These tumors have a tendency to develop in older patients, and have a propensity for affecting women more than men. The standard of treatment is surgical excision with a margin of normal tissue. Given that not all patients are good surgical candidates, the role of different treatment modalities in the management of this tumor is discussed.

Keywords: cosmesis; malignant proliferating trichilemmal tumor; non-invasive; outer root sheath tumor; pilar tumor; proliferating trichilemmal cyst; radiotherapy; skin cancer; surgical management; trichilemmal tumor.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Figure 1
Figure 1. Clinical Photographs of Radical Radiotherapy Treatment of Malignant Proliferative Trichilemmal Tumor.
A) Ulcerative lesion on initial presentation to clinic; B) Three months following radiotherapy treatment of tumor; C) Seven months following radiotherapy treatment of the tumor; D) Two years following treatment of the tumor. The patient was treated with 4,500 cGy divided over 15 doses (3 weeks) of 9 MeV electrons. Note the residual temple hollowing with resolution of MPTT lesion and radiotherapy skin changes. MPTT: malignant proliferating trichilemmal tumors
Figure 2
Figure 2. Customized Lead Shielding for Patient Treatment, Including Right External Eye Lead Shield.
Note the superior (Sup), anterior (Ant), and posterior (Post) borders are demarcated in marker on the shielding.
See this image and copyright information in PMC

References

    1. Proliferating epidermoid cysts. Jones EW. Arch Derm. 1966;94:11–19. - PubMed
    1. Proliferating trichilemmal tumors: a review of the literature. Satyaprakash AK, Sheehan DJ, Sangueza OP. Dermatol Surg. 2007;33:1102–1108. - PubMed
    1. Proliferating pilar tumors: A clinicopathologic study of 76 cases with a proposal for definition of benign and malignant variants. Ye J, Nappi O, Swanson PE, Patterson JW, Wick MR. Am J Clin Pathol. 2004;122:566–574. - PubMed
    1. Primary neoplasms of the hair follicle. Histogenesis and classification. Headington JT, French AJ. Arch Dermatol. 1962;86:430–441. - PubMed
    1. Recurrent malignant proliferating trichilemmal tumour: local management with ethanol injection. Takenaka H, Kishimoto S, Shibagaki R, Nagata M, Noda Y, Yasuno H. http://onlinelibrary.wiley.com/doi/10.1046/j.1365-2133.1998.02477.x/full. Br J Dermatol. 1998;139:726–729. - PubMed

Publication types

LinkOut - more resources